Friday, February 20

Healthcare

Rezolute rises as FDA lifts clinical hold on hyperinsulinism therapy

09/10/20241 Min Read

Clinical FDA hold hyperinsulinism lifts Rezolute rises therapy

Previous ArticleEvaxion reports positive mid-stage trial data on lead cancer vaccine candidate EVX-01

Next Article Autonomix rises after it reports reduction of pain in pancreatic cancer treatment